Bio Rad Laboratories Stock Surges 11% on Reports of Activist Elliott Investment Management Stake

Key Stats for Bio Rad Laboratories Stock

• 1-week price change for Bio Rad Laboratories stock: 17%
• $BIO Share Price as of May. 19: $281
• 52-Week High: $343
• $BIO Stock Price Target: $293

Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>

What Happened?

Bio Rad Laboratories (BIO) stock jumped sharply after the Wall Street Journal reported that Elliott Investment Management — one of the world’s most aggressive activist investors — has built a sizable stake in the company.

• Elliott manages roughly $80 billion in assets and is known for pushing underperforming companies to unlock value, whether through management changes, strategic reviews, or outright sales.
• The report sent Bio Rad Laboratories stock surging because Elliott’s involvement often signals that change is coming.
• The firm has successfully taken on other founder-controlled companies in the past, including Pinterest and data center operator Switch.

The core of Elliott’s thesis appears straightforward.

• Bio-Rad holds a strategic investment in Sartorius, the German pharmaceutical equipment supplier, currently worth around $5 billion.
• That’s not far off from Bio-Rad’s entire market value of roughly $6.6 billion.
• In other words, the market is essentially valuing Bio-Rad’s entire operating business — instruments, diagnostics, digital PCR — at close to just $1.1 billion.

See analysts’ growth forecasts and price targets for Bio Rad Laboratories stock (It’s free) >>>

What the Market Is Telling Us About Bio Rad Laboratories Stock

Bio Rad Laboratories stock had already been under significant pressure before Elliott showed up. Shares peaked above $800 during the pandemic boom and have since fallen more than 70%.

• Operating margins are forecast at just 10% to 12% for 2026, well below peers like Thermo Fisher and Danaher.
• The company’s Q1 results reflected these struggles.
• Revenue came in at $592 million, down 4.2% on a currency-neutral basis.
• The Middle East conflict hit hard, costing roughly $11 million in Diagnostics revenue in the quarter alone.
• Full-year guidance was cut, with currency-neutral revenue now expected to fall between 3% and 0.5%.

None of that stopped Bio Rad Laboratories stock from surging on the Elliott news.

That’s because activists don’t buy struggling companies — they buy undervalued ones. And with Sartorius worth nearly as much as the whole company, there’s a clear argument that Bio-Rad’s stock is deeply mispriced.

Elliott also already owns a direct stake in Sartorius, giving it a unique angle here.

Any move to monetize or restructure Bio-Rad’s Sartorius position could be a major catalyst for Bio Rad Laboratories stock going forward.

Estimate a company’s fair value instantly (Free with TIKR) >>>

How Much Upside Does Bio Rad Laboratories Stock Have From Here?

With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.

All it takes is three simple inputs:

1. Revenue Growth
2. Operating Margins
3. Exit P/E Multiple

If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.

From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.

See a stock’s true value in under 60 seconds (Free with TIKR) >>>

Looking for New Opportunities?

• See what stocks billionaire investors are buying so you can follow the smart money.
• Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
• The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.

Disclaimer:

Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!